Avalon Pharma’s H1 2026 net profit rises 26% to SAR 55.7M; Q2 at SAR 28.8M

06/08/2026 Argaam Exclusive

Content Summary:

Loading data...

Comments Analysis:

Positive: 0%
Neutral: 0%
Negative: 0%
Comments Summary:Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original sources for complete details and to verify the accuracy of the information.

Avalon Pharma Co. reported a 26% year-on-year (YoY) increase in net profit to SAR 55.7 million for the first half of 2026, compared with SAR 44.2 million in H1 2025.



Financials (Million Riyal)

Item 6m 2025 6m 2026 Change‬
Revenues 215.02 266.61 24.0 %
Gross Income 133.90 166.11 24.1 %
Operating Income 50.84 64.56 27.0 %
Net Income 44.21 55.70 26.0 %
Average Shares 35.00 35.00 -
Earnings Per Share before unusual items (Riyals) 1.26 1.59 26.0 %
EPS (Riyal) 1.26 1.59 26.0 %

The pharmaceuticals manufacturer posted strong revenue growth in H1 2026, with sales increasing 24% year-on-year (YoY) to SAR 266.6 million.

 

Private sector contributed 71.9% of total revenue, with sales up 32.6% YoY to SAR 191.7 million. The public sector sales grew 5.7% YoY to SAR 52.3 million. Export revenue grew 7.5% YoY to SAR 22.6 million, representing 8.5% of total.

 

Net profit margin improved to 20.9% from 20.6% in H1 2025, supported by better product mix and sustained operational efficiencies.



Current Quarter Comparison (Million Riyal)

Compared With The
Item Q2 2025 Q2 2026 Change‬
Revenues 117.66 136.49 16.0 %
Gross Income 73.63 85.50 16.1 %
Operating Income 28.44 33.89 19.1 %
Net Income 24.81 28.80 16.1 %
Average Shares 35.00 35.00 -
Earnings Per Share before unusual items (Riyal) 0.71 0.82 16.1 %
EPS (Riyal) 0.71 0.82 16.1 %

The company reported a 16.1% YoY increase in Q2 2026 net profit to SAR 28.8 million, driven by a 16% YoY increase in revenue to SAR 136.5 million. Net profit margin remained stable at 21.1%, supported by a better product mix and ongoing cost-efficiency initiatives.

 

On a quarterly basis, net profit rose 7.1% from SAR 26.9 million in Q1 2026.

 

Shareholders’ equity (excluding minority interest) stood at SAR 445.55 million at the end of the period, compared with SAR 385.17 million at the end of the corresponding period last year.

 

Attached Documents

 

View More Financial Results

 

View other reports